Evidence map›Paper›PMID 41584719›Full record

ArticleJTO clinical and research reports2026

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From

Kaiwen Wang, Ceylan Altintas Taslic, Patricia de Groot, Mitchell A Parma, Alvaro Guimaraes Paula, Melody Caranto, Komal Shah, Mukulika Bose, Cole Ruoff, Loukia G Karacosta and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kaiwen WangDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ceylan Altintas TaslicDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patricia de GrootDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mitchell A ParmaDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alvaro Guimaraes PaulaDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Melody CarantoDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Komal ShahDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mukulika BoseCancer System Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cole RuoffGraduate School of Biomedical Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Loukia G KaracostaCancer System Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren A ByersDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Carl M GayDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianjun ZhangDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John V HeymachDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bingnan ZhangDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with

Indexed as

ALKCase reportLorlatinibSmall cell transformationTarlatamab

Identifiers

PMID41584719
PMCPMC12828416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.